Clearant Achieves Key Milestone in Direct Distribution of Tissue Implants to Surgeons, Hospitals and Clinics; Company Completes First Stage of Sales Force Hiring in Time for Launch of Cervical Bone Implants.

LOS ANGELES -- Clearant, Inc. (OTCBB:CLRI) today announced it has achieved the first important milestone in its direct distribution strategy with the hiring of four territory representatives. This team will focus on distributing cervical spinal allograft implants treated with the CLEARANT PROCESS to surgeons and hospitals in selected markets in the U.S.

"Last month, the Company outlined its plans to transition from a pure licensing provider to the tissue and biological industry to a direct distributor of Clearant Sterile Implants to surgeons, clinics and hospitals via a direct sales force," said Alain Delongchamp, Clearant's chief executive officer. "I am very pleased with the quality and background of the team we have brought together. Each one of these territory representatives has a successful track record in serving the spinal and orthopedic surgical community in their respective geographic market, and each has specific experience in representing implant providers, as their backgrounds include sales and sales management positions with firms such as Biomet, Zimmer and Depuy."

"Due to a relatively small number of surgeons performing a high percentage of bone implant procedures, we believe that these representatives can be highly effective in rapidly penetrating the market," said Mr. Delongchamp. "While the sales cycle to tissue banks through distributors represented a lengthy process, we feel that our ability to market directly to leading surgeons and medical institutions will dramatically reduce the sales cycle."

Currently, the top fifteen markets in the U.S. represent in excess of $200 million in bone implant sales. The top 30-50 surgeons in these markets perform approximately 80% of the procedures, allowing the Company to employ a highly targeted marketing effort.

According to Delongchamp, the Company plans to hire 3 to 7 additional territory representatives before the end of 2006.

About Clearant, Inc.

Clearant, Inc. is a leader in pathogen inactivation for biological products. Clearant has developed the patent-protected CLEARANT PROCESS, which substantially reduces all types of pathogens in biological products while maintaining the functionality of the underlying protein. The Company plans to distribute directly to surgeons, hospitals and clinics CLEARANT PROCESS sterile implants starting mid 2006; in addition, Clearant continues to license the CLEARANT PROCESS and provides its patented sterilization services to tissue banks and other biological products manufacturers. As of the end of 1Q 2006, Clearant had 10 license and service agreements with tissue banks. To-date more than 8,000 patients have been successfully implanted with a CLEARANT PROCESS sterile implants supplied by one of the Company's licensed partners. Whereas various competing sterilization methods only kill specific types of pathogens (such as bacteria or lipid-enveloped viruses) for specific products, the CLEARANT PROCESS reduces all types of pathogens for products across many market segments including tissue implants, plasma proteins, recombinant products, medical devices and blood products. Also, the CLEARANT PROCESS can be applied at various stages of product processing and/or manufacturing, including in the final packaging. For more information, please visit www.clearant.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, in particular statements regarding the ability of the Company's direct sales force to penetrate the market for sterile implants, and plans to hire additional sales representatives. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control, which may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, results of additional clinical studies, efficacy of the technology, intense competition and substantial regulation in the biotechnology industry, and additional risks discussed in the company's filings with the SEC, available on the SEC web site http://www.sec.gov.